

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

Human EGFR (Research Grade Cetuximab Biosimilar) PE-conjugated Antibody

RRID:AB_2942015

Type: Antibody

Proper Citation

R and D Systems Cat# FAB9577P, RRID:AB_2942015

Antibody Information

URL: http://antibodyregistry.org/AB_2942015

Proper Citation: R and D Systems Cat# FAB9577P, RRID:AB_2942015

Target Antigen: EGFR

Host Organism: Human

Clonality: monoclonal

Comments: Applications: Flow Cytometry

Antibody Name: Human EGFR (Research Grade Cetuximab Biosimilar) PE-conjugated Antibody

Description: This monoclonal targets EGFR

Target Organism: Human

Clone ID: Hu1

Antibody ID: AB_2942015

Vendor: R and D Systems

Catalog Number: FAB9577P

Alternative Catalog Numbers: FAB9577P-100

Record Creation Time: 20231110T031131+0000

Record Last Update: 20260901T032500+0000

Ratings and Alerts

No rating or validation information has been found for Human EGFR (Research Grade Cetuximab Biosimilar) PE-conjugated Antibody.

No alerts have been found for Human EGFR (Research Grade Cetuximab Biosimilar) PE-conjugated Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer cell, 43(1), 49.

Zhang D, et al. (2025) Validation of CCL20-driven CAR-?? T secreting PD-1 blockade with enhanced trafficking into solid tumor. iScience, 28(10), 113463.

Shukla D, et al. (2025) Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy. Molecular therapy : the journal of the American Society of Gene Therapy.

Reincke SM, et al. (2023) Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell, 186(23), 5084.